Cohance Lifesciences' Telangala API facility passes latest USFDA inspection

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, has received the Establishment Inspection Report (EIR) from the USFDA for its API Unit-IV, situated at IDA Nacharam, Telangana.

The inspection by the USFDA was carried out from 3rd March, 2025 to 7th March, 2025, the company said in a regulatory filing. Upon completion of this inspection, the USFDA issued a Form 483, with two observations, it added.

“We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations,” the company stated in its regulatory filing.

Regulatory Impact and Market Outlook

The receipt of a VAI classification suggests that while some objectionable conditions were observed, they do not warrant any regulatory or enforcement action, positioning the facility for continued supply to the US market. This is a critical development for Cohance, given the strategic importance of the USFDA-regulated market in its growth roadmap.

Recent Compliance Highlights

• The latest inspection outcome further strengthens the compliance track record of the company’s API manufacturing units.
• The company’s proactive regulatory engagement supports long-term customer trust, particularly with large global pharmaceutical partners.

Project Outlook

With the USFDA inspection successful closure and VAI status classification, Cohance Lifesciences Pvt. Ltd. is poised to take on its international business expansion plans with regulatory confidence.” This is likely to be welcomed by investors and stakeholders, as regulatory certainty tends to lead to better supply chain certainty and market access.

About Cohance Lifesciences

Cohance Lifesciences Limited, previously known as Suven Pharmaceuticals Limited, operates in the contract development and manufacturing organization (CDMO) space with a focus on specialty APIs and intermediates. The company has steadily built its global regulatory footprint through consistent quality adherence.

Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. The content is based on highly reliable resources. Still if there is any error it is deeply regretted. Write to us for getting any error corrected.

REF: https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_25052025214553_Cohance_USFDA_Inspection_May25_2025.pdf